Holen Sie sich die Stockscreener-App
0.4551
1.13%
0.0051
Vorhandelsmarkt:
.48
0.0249
+5.47%
BiomX Inc Aktie (PHGE) Neueste Nachrichten
BiomX Inc. Achieves Breakthrough in Treating Antibiotic-Resistant Infections - citybuzz -
BiomX Stock Could Soar 3000% As This $10M Biotech Cracks The 'Superbug' Code, Wall Street Says - FinancialContent
BiomX Highlights Progress in Phage Therapy Advancements - TipRanks
BiomX (NYSEAMERICAN:PHGE) Shares Down 4.3% – Here’s What Happened - Defense World
Biomx stock plunges to 52-week low, hitting $0.47 By Investing.com - Investing.com South Africa
Biomx stock plunges to 52-week low, hitting $0.47 - Investing.com Australia
BiomX (NYSEMKT:PHGE) Stock Price Down 32.6% – What’s Next? - Defense World
Bacteriophage Therapy Market is Booming Worldwide |Enbiotix,Micreos,BiomX - openPR.com
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conf - GuruFocus
BiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 Conference - Nasdaq
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference - GlobeNewswire
BiomX Breakthrough: Phase 2 Success in Fighting Antibiotic-Resistant Diabetic Foot Infections - Stock Titan
BiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call Transcript - MSN
HC Wainwright Issues Pessimistic Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World
BiomX Inc. Earnings Call: Optimism and Progress - TipRanks
PHGE: HC Wainwright & Co. Maintains Buy Rating, Lowers Price Tar - GuruFocus
BiomX (PHGE) Price Target Reduced by Analyst Yet Buy Rating Maintained | PHGE Stock News - GuruFocus
BiomX Inc (PHGE) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - Yahoo Finance
BiomX Inc. Reports Q1 2025 Progress and Financials - TipRanks
BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BiomX Inc. SEC 10-Q Report - TradingView
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates - TradingView
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates | PHGE Stock News - GuruFocus
BiomX Breakthrough: Phase 2 Trial Reveals 40% Superior Efficacy in Fighting Antibiotic-Resistant Infections - Stock Titan
BiomX (PHGE) to Release Quarterly Earnings on Thursday - Defense World
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 - GlobeNewswire
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 | PHGE Stock News - GuruFocus
BiomX Inc. to Host Conference Call for First Quarter 2025 Financial Results and Business Updates - Nasdaq
JPMorgan Chase & Co. Invests $314,000 in BiomX Inc. (NYSEMKT:PHGE) - Defense World
Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Decreases By 48.2% - Defense World
BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
HC Wainwright Reiterates “Buy” Rating for BiomX (NYSEMKT:PHGE) - Defense World
Q1 Earnings Estimate for BiomX Issued By HC Wainwright - Defense World
What is HC Wainwright’s Estimate for BiomX FY2025 Earnings? - Defense World
What is HC Wainwright’s Forecast for BiomX Q1 Earnings? - Defense World
HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy By Investing.com - Investing.com South Africa
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy - Investing.com India
Biomx stock plunges to 52-week low, hits $0.48 - Investing.com
Biomx stock plunges to 52-week low, hits $0.48 By Investing.com - Investing.com India
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewswire
BiomX stock target soars to $21 on Phase 2 trial success - Investing.com India
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):